Table 1 Clinical and molecular characteristics of the total series of colorectal cancer patients within the Netherlands Cohort Study (NLCS; 1986-2006), as well as according to SARIFA-status (SARIFA-positive and SARIFA-negative)

Age at diagnosis in years, median (range)

74.0 (55.0-89.0)

74.0 (55.0-89.0)

74.0 (55.0-88.0)

0.355^b

Sex, n (%)

 Men

958 (55.5)

694 (56.4)

264 (53.2)

0.233

 Women

769 (44.5)

537 (43.6)

232 (46.8)

Tumour location, n (%)

 Colon

1288 (74.6)

863 (70.1)

425 (85.7)

<0.001

 Rectosigmoid

177 (10.3)

142 (11.5)

35 (7.1)

 Rectum

262 (15.2)

226 (18.4)

36 (7.3)

pTNM stage, n (%)

 I

315 (18.2)

309 (25.1)

6 (1.2)

<0.001

 II

672 (38.9)

514 (41.8)

158 (31.9)

 III

454 (26.3)

277 (22.5)

177 (35.7)

 IV

245 (14.2)

103 (8.4)

142 (28.6)

 Unknown

41 (2.4)

28 (2.3)

13 (2.6)

Tumour extension (pT), n (%)

 T1

65 (3.8)

65 (5.3)

-

<0.001

 T2

306 (17.7)

297 (24.1)

9 (1.8)

 T3

1138 (65.9)

764 (62.1)

374 (75.4)

 T4

174 (10.1)

76 (6.2)

98 (19.8)

 Unknown

44 (2.6)

29 (2.4)

15 (3.0)

Lymph node involvement (pN), n (%)

 N0

900 (52.1)

731 (59.4)

169 (34.0)

<0.001

 N+

629 (36.4)

344 (27.9)

285 (57.5)

 Unknown

198 (11.5)

156 (12.7)

42 (8.5)

Differentiation grade, n (%)

 Well

152 (8.8)

125 (10.2)

27 (5.4)

<0.001

 Moderate

1138 (65.9)

845 (68.6)

293 (59.1)

 Poor/undifferentiated

312 (18.1)

164 (13.3)

148 (29.8)

 Unknown

125 (7.2)

97 (7.9)

28 (5.7)

Adjuvant therapy, n (%)

 No

1426 (82.6)

1046 (85.0)

380 (76.6)

<0.001

 Yes

282 (16.3)

172 (14.0)

110 (22.2)

 Unknown

19 (1.1)

13 (1.1)

6 (1.2)

MMR status, n (%)

 Proficient

1537 (89.0)

1086 (88.2)

451 (90.9)

0.104

 Deficient

190 (11.0)

145 (11.8)

45 (9.1)

 Unknown

-

-

-